A smarter steroid schedule might tame Chemotherapy's blood sugar spike
NCT ID NCT03505762
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial tests whether adjusting the dose of prednisone, a steroid in the R-CHOP chemotherapy regimen, can prevent high blood sugar (hyperglycemia) in adults with B-cell non-Hodgkin lymphoma. Participants are randomly assigned to either the standard prednisone dose or a tailored reduction based on their blood sugar levels. The goal is to see if a lower, personalized steroid dose can keep blood sugar in check without compromising lymphoma treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tailored prednisone reduction
- What this could lead to
- If effective, this approach could help manage blood sugar levels during chemotherapy, potentially reducing complications and improving treatment tolerability.
- What could go wrong
- This is a small phase II pilot, so results may not be definitive. Reducing prednisone could affect lymphoma control, and the approach may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
80 people
The number who actually took part.
- Started
-
Jul 2018
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of B cell non-Hodgkin lymphoma confirmed by World Health Organization (WHO) criteria * Planned treatment with R-CHOP chemotherapy * 18 years of age or older * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3 * Life expectancy of greater than 3 months with chemotherapy * The effects of R-CHOP on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document Exclusion Criteria: * Uncontrolled human immunodeficiency virus (HIV), CD4 count \< 50 * Diagnosis of primary central nervous system (CNS) lymphoma * Unable to receive R-CHOP chemotherapy * History of severe (i.e. anaphylactic) allergic reactions attributed to compounds of similar chemical or biologic composition to glucocorticoids and other component of R- * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection not controlled with antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia that cannot be rate controlled with medications, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because R-CHOP includes D Class agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with R-CHOP, breastfeeding should be discontinued if the mother is treated with these agents
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-cell non Hodgkin lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets tough Non-Hodgkin's lymphoma
- New drug joins standard chemotherapy in fight against B-Cell lymphoma
- New antibody tested against aggressive blood cancer
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- New drug combo aims to tackle Hard-to-Treat lymphoma